AKT1 and prostate cancer: In this way, IL-6 could trigger the PI3K/Akt, NF-κB and MAPK/ERK signaling pathways in a manner similar to that observed in other tumors such as prostate cancer with the upregulation of cyclin A1 [50], or bladder cancer and multiple myeloma [35, 21].